Drugs / [225Ac]Ac-A9-3408
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07076550 | Nov 2025 → Jan 2028 expected | metastatic melanoma, mucosal melanoma, uveal melanoma | Alpha-9 Oncology USA Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [225Ac]Ac-A9-3408 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07076550 ↗ |
| Route | Intravenous | “Administered IV” NCT07076550 ↗ |